WO2021063201A1
|
|
Anti-pd-1 antibody and use thereof
|
WO2021047406A1
|
|
Tricyclic compound, pharmaceutical composition containing same, preparation method therefor and use thereof
|
WO2021047407A1
|
|
Biaryl compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
|
WO2021043077A1
|
|
Substituted pyrazine compound and preparation method therefor and use thereof
|
WO2021057256A1
|
|
Heterocyclic nitrogen compound, pharmaceutical composition containing same, preparation method therefor and use thereof
|
WO2021027594A1
|
|
Imidazolopyrimidine compounds comprising fused ring group, preparation method therefor and use thereof
|
CN112142730A
|
|
Solid forms of heteroaryltetrahydropyridines and process for their preparation
|
WO2020238740A1
|
|
Solid form of aromatic compound and preparation method therefor
|
WO2020221038A1
|
|
Benzothiophene compound, preparation method therefor and use thereof
|
WO2020211674A1
|
|
Anti-fxi/fxia antibody and use thereof
|
WO2020207352A1
|
|
Triazine benzimidazole compounds and medical use thereof
|
WO2020207263A1
|
|
Benzimidazole compound, preparation method therefor and use thereof
|
WO2020182018A1
|
|
Nitrogen heterocyclic compound, preparation method therefor and use thereof
|
WO2020173364A1
|
|
Oral pharmaceutical composition with azetidine derivative as active ingredient, and preparation method therefor and use thereof
|
WO2020135210A1
|
|
Substituted aryl compound and preparation method therefor and use thereof
|
WO2020135201A1
|
|
Antibody and use thereof
|
WO2020135195A1
|
|
Aminopyridine compound, preparation method therefor and use thereof
|
WO2020114307A1
|
|
Isoxazole derivative, preparation method therefor and use thereof
|
WO2020108343A1
|
|
Oral pharmaceutical composition using 4'-thionucleoside compound as active ingredient, preparation method therefor and use thereof
|
WO2020098563A1
|
|
Pharmaceutical composition comprising polypeptide compound, preparation method therefor and use thereof
|